The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
NMN, NR, Niacin
NAD+ is the most legitimate longevity target in this book and the most commercially exploited. These two things are not in tension — the legitimacy is precisely what made it commercially exploitable. The biology is real. The commercial claims have outrun the clinical evidence. Both deserve to be said clearly.
The central tension resolved: NAD+ declines with age in human tissue. The decline contributes to mitochondrial dysfunction, reduced DNA repair, impaired sirtuin signaling, and accelerated aging phenotypes. Restoring NAD+ in old mice reverses multiple aging phenotypes in multiple independent labs. The animal evidence is compelling and replicable. Human clinical trials find that NMN and NR reliably raise blood NAD+ levels and produce modest improvements in metabolic function and physical performance in specific populations. Independent meta-analyses in 2024-2025 consistently find that 'most clinically relevant outcomes were not significantly different' from placebo and that 'exaggeration of benefits may exist in the field.' Two of the most prominent voices advocating for specific NAD+ precursors — Sinclair for NMN, Brenner for NR — both have direct commercial interests in the precursor they advocate for. The truth likely lives between their positions: NAD+ supplementation probably does something modestly beneficial for aging humans, probably less dramatically than the commercial discourse implies, and probably through mechanisms that the current clinical trials haven't been long enough or large enough to fully characterize.
What the evidence currently supports with confidence: oral NMN or NR reliably raises blood NAD+; modest improvements in insulin sensitivity, physical performance, and liver enzymes in specific populations; a good safety profile. What the evidence does not support: 'reversing aging,' dramatic longevity extension, or a clear clinical superiority of expensive NMN/NR over cheap niacinamide for most applications.
NAD+ has been known since 1906, when Arthur Harden and William John Young noticed that a mysterious substance in boiled yeast extract was essential for fermentation. By the 1930s, it was understood as a coenzyme essential for cellular respiration — a molecule that shuttles electrons through the metabolic machinery that converts food to ATP. For decades, NAD+ was basic biochemistry: essential, ubiquitous, and not particularly interesting from a drug development perspective. Then two things happened in the 2000s and 2010s that transformed it from a textbook molecule into a multi-billion dollar supplement category.
The first was the discovery of sirtuins. SIRT1-7 are a family of proteins that were found to extend lifespan in model organisms when activated — and that required NAD+ as an essential cofactor for their enzymatic activity. Sirtuins are histone deacetylases and ADP-ribosyltransferases that regulate gene expression, DNA repair, metabolic adaptation, and cellular stress response. If sirtuins extend lifespan and require NAD+ to function, then declining NAD+ with age could explain declining sirtuin activity, which could explain accelerating aging. This logic — elegant, compelling, and somewhat simplified — drove an enormous amount of research and excitement in the longevity field.
The second was the NAD+ aging decline observation. Multiple independent studies documented that NAD+ levels in human tissue decline substantially with age — roughly 50% reduction between the third and seventh decades. In mice, supplementation with NAD+ precursors reversed this decline and produced dramatic rejuvenation phenotypes: improved mitochondrial function, better metabolic health, restored muscle function in aged animals, and in some studies, extended lifespan. The animal evidence was genuinely impressive and generated in multiple independent laboratories.
David Sinclair at Harvard Medical School became the most prominent public face of this research. His laboratory published foundational work on sirtuins, NAD+ biology, and aging. His 2019 book 'Lifespan: Why We Age — and Why We Don't Have To' brought these ideas to a mass audience with enthusiasm and optimism that outpaced what the human clinical evidence at the time supported. He took NMN himself, discussed his supplement regimen publicly and frequently, and positioned himself as a first-mover in applying his own research. He was also, as would become increasingly relevant, commercially invested in the NAD+ ecosystem through MetroBiotech and multiple other companies.
The market responded. NMN and NR became two of the fastest-growing supplement categories in longevity. By the mid-2020s, hundreds of products claimed to 'boost NAD+,' 'reverse aging,' or 'restore cellular youth.' Prices ranged from tens to hundreds of dollars per month. Human trials began. And when the human trial data started coming in systematically — through meta-analyses and independent systematic reviews published between 2024 and 2025 — the picture that emerged was more nuanced than the commercial narrative: NAD+ blood levels reliably increase with supplementation; most clinically relevant outcomes improve modestly or inconsistently; the 'reverse aging' framing is not supported by the controlled human trial evidence currently available.
THE CENTRAL TENSION — NAVIGATING THE COMMERCIAL BATTLEFIELD
NAD+ is the most commercially contested topic in this book. Two credentialed Harvard-affiliated scientists with opposing financial interests — Sinclair (aligned with NMN via MetroBiotech) and Brenner (aligned with NR via ChromaDex/TruNiagen) — have conducted their scientific debate partly in public, partly on social media, and with commercial stakes on both sides. Every piece of NAD+ research should be read with the question: who funded it, who published it, and what do they sell? This doesn't mean the research is wrong. It means the provenance matters more here than for most topics in science, and the community deserves to know the financial landscape before evaluating the claims within it.
The animal evidence is extensive and compelling. The human evidence is real, expanding, and considerably more modest than the commercial discourse implies. Both are documented here with their appropriate grades.
The most consistently positive clinical finding in NMN human trials is modest insulin sensitivity improvement in specific populations. Yoshino et al. (Science, 2021) [3] — the most widely cited NMN human RCT — found that 250 mg/day NMN for 10 weeks in overweight, postmenopausal women with prediabetes improved muscle insulin sensitivity (measured by euglycemic clamp) and insulin signaling gene expression. The effect was real and statistically significant. It was also modest in absolute magnitude and specific to this population. A 2024 meta-analysis of NMN effects on glucose and lipid metabolism found overall significant blood NAD+ elevation but noted that 'most of the clinically relevant outcomes were not significantly different between NMN supplementation and control group' across the pooled studies. Grade B: real but modest effects in specific populations; not a universal metabolic cure.
Systematic review (Wen et al., Cureus, 2024) [7]: 10 RCTs, 437 patients, mean age 58. NMN improved physical performance outcomes (gait speed, 6-minute walk test, five-times sit-to-stand). The 2024 meta-analysis (Tandfonline) found significant effects on gait speed (SMD 0.34 m/s) and modest effects on muscle function. The 2025 meta-analysis (Journal of Cachexia, Sarcopenia and Muscle): 'NMN and NR supplementation offer minimal benefits for sarcopenia and muscle performance in older adults.' The variation in conclusions across these meta-analyses reflects: different included studies, different populations, different endpoints, and different follow-up durations. The honest synthesis: some physical performance benefit exists, particularly in older adults with baseline metabolic impairment; effect sizes are modest; long-term data is limited. Grade B overall; Grade B-C for older adults with sarcopenia specifically.
NAD+ is essential for cardiac energy metabolism. Cardiac NAD+ decline contributes to heart failure pathology. Animal models show NMN and NR restore cardiac function in heart failure models. Human clinical data: early trials in heart failure patients and at-risk populations are ongoing. NR has been studied in heart failure (HAIG trial) — results published showing NAD+ elevation without significant clinical benefit on primary outcomes. The cardiovascular application represents one of the most mechanistically compelling cases for NAD+ supplementation and one of the most disappointing in terms of human clinical translation thus far. Grade C: animal evidence strong; human cardiovascular trial results modest.
NAD+ declines in the aging brain; NAD+ depletion accelerates neurodegeneration in animal models of Alzheimer's and Parkinson's. NR supplementation raised NAD+ in plasma extracellular vesicles enriched for neuronal origin in a human pilot study (Vreones et al., Aging Cell, 2023) — providing the first evidence that oral NR might reach the neuronal compartment. A crossover trial of NR in subjective cognitive decline and mild cognitive impairment is registered and underway. Grade C: compelling mechanistic case and some early human signals; no completed cognitive outcome RCT.
The most expansive claim — that NAD+ supplementation slows or reverses aging — is the hardest to evaluate and the most commercially promoted. Animal lifespan extension with NAD+ precursors has been documented in multiple labs (C. elegans, mice). Human longevity biomarkers (telomere length, epigenetic age clocks, inflammatory markers) have been modestly improved in some NMN/NR trials. Whether these biomarker changes translate to meaningful longevity extension in humans cannot be determined from trials of 10-12 weeks duration. The claim that NAD+ supplementation 'reverses biological aging' in humans is unsupported by controlled trial evidence. Grade C-D: animal longevity evidence well-established; human longevity benefit unproven.
The 2024 meta-analysis found a significant effect of NMN on ALT reduction (SMD -0.29 IU/L) in the combined analysis — suggesting liver enzyme normalization as a consistent and reproducible benefit. NAD+ is critical for hepatic metabolism; NAFLD (non-alcoholic fatty liver disease) is associated with hepatic NAD+ depletion. The liver health signal is one of the more consistent and objectively measured findings in the NMN human trial literature. Grade B.
NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme present in every cell of every living organism. Molecular weight 663 Da. It exists in two interconvertible forms: NAD+ (oxidized) and NADH (reduced). This oxidation-reduction cycling is the core of its biochemical function — NAD+ accepts electrons from metabolic reactions, becoming NADH, which then donates electrons to the electron transport chain to produce ATP. Beyond its redox function, NAD+ is a substrate (not just a cofactor) for three critical enzymatic classes: sirtuins (SIRT1-7, NAD+-dependent protein deacetylases — epigenetic regulators), PARPs (poly-ADP-ribose polymerases — DNA repair enzymes), and CD38/CD157 (ADP-ribosyl cyclases — immune and calcium signaling). The consumption of NAD+ by these enzymes is significant: PARP activity during DNA damage can deplete 80% of cellular NAD+ within minutes. This consumption is not just a side effect — the enzymes only work when they consume NAD+.
NAD+ levels in human tissue decline with age — this is one of the most robustly documented facts in the aging biology field. Multiple independent cohort studies document approximately 50% decline in whole-blood and tissue NAD+ between the third and seventh decades. The mechanisms: (1) NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in NAD+ biosynthesis from nicotinamide, declines in activity with age in multiple tissues; (2) PARP enzyme activity increases with aging (due to accumulating DNA damage), consuming more NAD+; (3) CD38 expression increases dramatically with aging and inflammation — CD38 consumes NAD+ as a calcium signaling messenger and its upregulation with inflammaging is one of the most significant drivers of age-related NAD+ decline. Grade A: age-related NAD+ decline is among the most independently replicated findings in aging biology.
The body produces NAD+ through multiple routes: (1) De novo synthesis from tryptophan via the kynurenine pathway — the longest route; (2) The Preiss-Handler pathway from niacin (nicotinic acid); (3) The salvage pathway from nicotinamide (niacinamide) via NAMPT → NMN → NAD+ — the primary route for recycling NAD+ metabolites; (4) The NRK pathway from NR — through nicotinamide riboside kinase (NRK) to NMN, then to NAD+. All four precursor supplementation strategies (niacin, niacinamide, NR, NMN) feed into these pathways at different points. The salvage pathway is the most important for NAD+ homeostasis in adult tissues.
THE PRECURSOR LANDSCAPE — WHAT ACTUALLY DIFFERS BETWEEN COMPOUNDS
NMN → NAD+ directly (one enzymatic step via NMNAT enzymes). NR → NMN → NAD+ (two steps: NRK converts NR to NMN; NMNAT then converts NMN to NAD+). Niacin (nicotinic acid) → via the Preiss-Handler pathway → NAD+ (multiple steps but well-established). Niacinamide (nicotinic acid amide, NAM) → via NAMPT → NMN → NAD+ (salvage pathway, same as NMN's downstream steps). KEY PRACTICAL QUESTION: Does the extra step for NR vs NMN, or the multiple steps for niacin, translate into meaningfully different NAD+ elevation in humans? The evidence suggests: all four raise blood NAD+; NR may raise it slightly more than NMN in some comparisons; niacin effectively raises NAD+ at far lower cost. Whether the specific tissue distribution of NAD+ elevation differs between precursors in ways that matter clinically is unknown.
The mechanistic case for NAD+ supplementation is genuinely compelling. Restoring a declining essential coenzyme should produce functional improvements across every process that coenzyme supports. The question — which comes up repeatedly in the human trial data — is whether the modest NAD+ increases achievable through oral supplementation translate to clinically meaningful improvements in the downstream processes that require it.
SIRT1 and SIRT3 are the best-characterized sirtuins for aging and metabolism. SIRT1 in the nucleus deacetylates histones and transcription factors, regulating gene expression programs relevant to metabolism, stress response, and DNA repair. SIRT3 in the mitochondria deacetylates and activates metabolic enzymes of the TCA cycle and electron transport chain. Both require NAD+ as a co-substrate that is consumed during deacetylation. When NAD+ declines, sirtuin activity declines proportionally — providing the mechanistic link between NAD+ decline and aging-associated epigenetic and metabolic dysfunction. Whether supplementation raises NAD+ enough to meaningfully increase sirtuin activity at the cellular level (as opposed to raising blood NAD+ biomarkers) is the key translation question. Grade B: sirtuin/NAD+ interdependence is well-established (A-level biology); the clinical benefit of supplementation-driven sirtuin activation in humans is less certain.
PARP1 is the primary cellular emergency responder to DNA damage — it detects strand breaks and synthesizes poly-ADP-ribose chains to recruit repair machinery. Each PARP1 activation event consumes 2-3 NAD+ molecules. During ongoing DNA damage (from UV, reactive oxygen species, or replication errors), PARP1 can deplete cellular NAD+ rapidly. Declining NAD+ with age means declining PARP1 activity means declining ability to repair DNA damage — a potential contribution to the genomic instability hallmark of aging. Supplementation that restores cellular NAD+ should theoretically restore PARP1 function. Grade B-C: mechanism well-established; clinical DNA repair benefit in humans from supplementation not directly measured.
NAD+ is essential for Complex I of the electron transport chain (accepting electrons from NADH) and for TCA cycle enzymes that generate NADH. Declining cellular NAD+ impairs electron transport chain efficiency, reducing ATP production and increasing mitochondrial ROS. Sirtuin-mediated activation of PGC-1α — the master regulator of mitochondrial biogenesis — also requires NAD+. Supplementation that raises cellular NAD+ should improve mitochondrial function through both the bioenergetic and the sirtuin-regulatory mechanisms. Animal models consistently show this. Human studies show some evidence of improved metabolic function (insulin sensitivity, exercise capacity) but the effect sizes are modest. Grade B-C.
CD38 is a membrane-bound enzyme that is the primary consumer of extracellular NAD+. It is expressed on immune cells and many other cell types, and its expression increases dramatically with aging, metabolic disease, and chronic inflammation — the same conditions that already reduce NAD+ synthesis. The net effect: as you age, you produce less NAD+ and consume more of it through CD38. Some researchers argue that supplementation alone cannot meaningfully raise cellular NAD+ when CD38 activity is very high, because the supplemental NAD+ is consumed by CD38 before it can reach the intracellular pools where sirtuins and PARPs operate. This is why some sophisticated NAD+ protocols include CD38 inhibitors — primarily quercetin (also a senolytic) and apigenin — to reduce the consumption rate while supplementing the production rate. Grade B: CD38's role in NAD+ decline is well-established; whether routine supplementation doses meaningfully overcome CD38-mediated consumption in aging humans is not definitively resolved.
THE CD38/NAD+ ANTAGONISM — WHY 'JUST TAKE MORE' MAY NOT WORK
The standard supplement-industry framing: take NMN or NR, raise NAD+, feel younger. The more complete picture: if CD38 activity is high (as it is in anyone with significant age-related inflammation), the supplemental NAD+ precursors may be metabolized by CD38 at the extracellular and blood level before reaching intracellular compartments where sirtuin and PARP enzymes operate. This is why bloodwork showing raised whole-blood NAD+ after supplementation does not necessarily mean the sirtuins in your cells are better supplied. The cells-that-need-it-most / cells-consuming-it-most tension is one of the most important nuances in NAD+ biology that the commercial discourse ignores.
This section is where commercial interest and scientific evidence collide most visibly. Understanding who is saying what, and why they might say it, is as important as understanding the biochemistry.
David Sinclair (Harvard Medical School): co-founder of MetroBiotech (NMN producer), involved with 28+ companies many in anti-aging, commercial interests in NMN specifically. Has published extensively on NMN, takes it personally, and has promoted it in his book and public appearances. Charles Brenner (City of Hope): Chief Scientific Advisor for ChromaDex, which manufactures NIAGEN (the leading NR supplement), discoverer of NR as a vitamin B3 form in 2004. Has extensively criticized Sinclair's research claims and promoted NR as the superior precursor. ChromaDex vs MetroBiotech is a commercial competition. Sinclair vs Brenner is partly a scientific debate and partly a commercial dispute. Both men's scientific contributions are real. Neither is an objective neutral voice on which precursor is superior.
NMN (nicotinamide mononucleotide) is the molecule one enzymatic step from NAD+. Molecular weight 334 Da. Sinclair's lab used NMN extensively in mouse studies and this drove the community's initial enthusiasm. The Slc12a8 transporter in the small intestine was proposed as a mechanism for direct NMN absorption, though its relative contribution to bioavailability remains disputed. Human clinical trials: multiple RCTs showing blood NAD+ elevation (Grade A). Physical performance improvements in older adults (Grade B). Insulin sensitivity improvements (Grade B, modest effect size). The 2024 meta-analysis (Tandfonline) found: NMN reliably raises blood NAD+ but 'most of the clinically relevant outcomes were not significantly different between NMN supplementation and control group.' The FDA's 2022 ruling that NMN may be excluded from supplement status due to prior IND (investigational new drug) applications was controversial and largely unenforced — NMN products remain widely available as of 2026. Standard doses: 250-1,000 mg/day. Cost: typically $50-100/month for quality NMN.
NR (nicotinamide riboside) was discovered as a form of vitamin B3 by Brenner in 2004. It enters NAD+ biosynthesis via the NRK pathway: NR → NMN → NAD+. NIAGEN (ChromaDex's NR) has FDA GRAS status, has been notified to FDA as a New Dietary Ingredient, and has been accepted as safe by regulatory agencies in Australia, New Zealand, Europe, Canada, and Brazil — a broader regulatory acceptance than NMN's somewhat uncertain US status. Approximately 40+ published human clinical studies. A 2018 trial (Trammell et al., Nature Communications) showed 500 mg NR twice daily raised blood NAD+ by ~60% in healthy adults. NR has been studied in Parkinson's disease, heart failure, and cognitive decline populations. Standard doses: 250-1,000 mg/day. Cost: comparable to NMN, $40-100/month.
NR vs NMN head-to-head: limited direct comparison data exists. One comparison of separate human studies suggests NR may raise whole-blood NAD+ approximately 25% more than NMN at comparable doses — but this is an indirect comparison, not a randomized head-to-head trial. The 2025 meta-analysis (Journal of Cachexia, Sarcopenia and Muscle) analyzed both together and found 'minimal benefits for sarcopenia and muscle performance in older adults' from either compound.
THE NIACIN QUESTION THAT NOBODY IN THE SUPPLEMENT INDUSTRY WANTS TO ANSWER
Niacin (nicotinic acid, niacinamide) is the simplest, oldest, most extensively studied form of vitamin B3. Both forms raise NAD+. Niacinamide (nicotinic acid amide, also called NAM) does not cause the skin flushing of niacin and has been used in doses of 25-500 mg for various indications for decades. It is FDA GRAS. It costs roughly $0.05-0.10 per day at 500 mg. NMN and NR cost $1.50-3.00 per day at comparable doses. The legitimate scientific question is: do NMN and NR raise NAD+ more effectively, or in more therapeutically relevant tissue compartments, than simple niacin/niacinamide — to a degree that justifies 20-60x higher cost? The honest answer: the head-to-head human comparison data is limited, and the commercial players who sell NMN and NR have every incentive not to fund it. Niacin and niacinamide cannot be patented. A study showing they're as effective as NMN would destroy the premium supplement category. That study has not been done.
Practical niacin/niacinamide notes: niacin (nicotinic acid) causes skin flushing (prostaglandin D2-mediated) at doses above ~100 mg that most people find uncomfortable and that some mistake for an allergic reaction — it is not dangerous, just unpleasant. Niacinamide (the amide form) does not cause flushing. Both raise NAD+ via different entry points in the biosynthesis pathway. High-dose niacinamide (>1 gram/day) can inhibit SIRT1 (acting as a substrate inhibitor of sirtuin activity) — an ironic dose-dependent effect where too much of the NAD+ precursor suppresses the very enzyme the NAD+ is supposed to support. This effect has been documented in cell culture; whether it is relevant at typical supplementation doses is not definitively established.
THE HONEST META-ANALYSIS CONCLUSIONS — 2024-2025
The most important document in the NAD+ chapter is not a clinical trial paper — it is the 2024 meta-analysis published in Critical Reviews in Food Science and Nutrition (Tandfonline): 'Random-effects meta-analyses found an overall significant effect of NMN supplementation in elevating blood NAD levels. However, most of the clinically relevant outcomes were not significantly different between NMN supplementation and control group. Together, our findings suggest that an exaggeration of the benefits of NMN supplementation may exist in the field.' This is the independent scientific community's current best assessment of the controlled trial evidence. The word 'exaggeration' is unusual in a peer-reviewed meta-analysis. It is deliberately placed.
Outcome
Best Evidence
Grade
Key Finding
Limitation
Blood NAD+ elevation
Multiple RCTs (NMN + NR)
A
Reliable, dose-dependent elevation (40-100% increase)
Blood NAD+ ≠ cellular NAD+ in all compartments; biomarker ≠ clinical outcome
Insulin sensitivity
Yoshino et al. 2021 (Science)
B
Improved in overweight postmenopausal prediabetic women (250 mg NMN x 10 weeks)
Specific population; modest effect; not replicated across all metabolic populations
Physical performance (older adults)
10 RCT systematic review (Wen 2024)
B
Significant improvements in gait speed, walk tests
Modest effect sizes; 2025 meta-analysis: 'minimal benefits' for sarcopenia
Liver enzymes (ALT)
2024 meta-analysis
B
Significant ALT reduction (SMD -0.29)
Modest effect; clinical significance unclear
Cardiovascular outcomes
HAIG trial + others
C
NAD+ elevated but primary clinical endpoints modest
Trial results not meeting primary endpoints
Cognitive function
Pilot studies; trial underway
C
NR reaches neuronal compartment; cognitive outcome trial not complete
No completed cognitive outcome RCT
Longevity / anti-aging
Animal models; biomarker studies
C-D
Animal lifespan extended; human biomarker changes modest
No human longevity trial; biomarkers ≠ longevity proof
Sarcopenia (muscle mass, older adults)
2025 meta-analysis (J Cachexia)
B-C
'Minimal benefits for sarcopenia and muscle performance'
Negative meta-analysis finding; contradicts some individual trials
Precursor
Cost/Month
FDA Status
Human Trials
Key Advantage
Key Limitation
NMN
$50-100
Complex (NDI/drug exclusion debate); widely available
40+ RCTs
One step from NAD+; Sinclair-endorsed ecosystem
More expensive; uncertain regulatory status; no clear head-to-head superiority over NR
NR (NIAGEN)
$40-80
GRAS + NDI approved; broadest international regulatory acceptance
40+ clinical studies
Broadest regulatory approval; most clinical trial experience; no flushing
Two steps to NAD+; Brenner commercially aligned with NR
Niacinamide (NAM)
$5-15
GRAS; OTC vitamin
Decades of use; less specific NAD+ trials
Cheapest; well-tolerated; widely available; effective
High doses (>1g) may inhibit sirtuins; not as studied as precursor specifically
Niacin (nicotinic acid)
$3-10
GRAS; OTC vitamin
Extensive cardiovascular literature
Cheapest; well-absorbed; dual cardiovascular + NAD+ benefits
Flushing at doses above 100mg limits tolerability for many users
NAD+ IV infusion
$200-600/session
Clinical setting only
Limited comparative data
Highest acute blood NAD+ elevation
No evidence of superiority over oral precursors for chronic outcomes; expensive; inconvenient
NMN human trial doses: 125-1,200 mg/day. Most positive findings in the 250-500 mg/day range. No controlled dose-response study has clearly established the optimal human dose. Higher is not necessarily better — and given NMN's partial conversion to nicotinamide, high doses carry the theoretical sirtuin-inhibition concern of excess nicotinamide. NR human trial doses: 250-2,000 mg/day. Safety up to 2,000 mg/day for 12 weeks has been documented (no serious adverse events). Most trials use 500-1,000 mg/day. Niacinamide: 25-500 mg/day for general use. Avoid sirtuin-inhibiting doses above 1 gram/day for longevity applications.
Goal
Compound
Dose
Frequency
Notes
Blood NAD+ elevation (proven)
NMN or NR
500 mg
Daily
Both raise blood NAD+ reliably at this dose
Metabolic support (insulin, liver)
NMN
250-500 mg
Daily with food
Matches doses in positive metabolic trials
Physical performance (older adults)
NMN or NR
250-500 mg
Daily
Effect size modest; combine with resistance training
Budget-conscious NAD+ support
Niacinamide
250-500 mg
Daily
Far cheaper; effective NAD+ precursor; avoid >1g
CD38 inhibition stack
NMN/NR + quercetin
500 mg + 500 mg
Daily
Rationale: raise precursor supply + reduce consumption
NAD+ IV infusions (500-1,000 mg NAD+ administered intravenously over 1-4 hours) are offered at longevity clinics, some anti-aging practices, and wellness centers at prices of $200-600 per session. The rationale: IV delivery bypasses GI conversion and delivers NAD+ directly to the bloodstream. The evidence: blood NAD+ levels increase acutely after IV infusion. Whether this acute blood NAD+ elevation produces better cellular NAD+ elevation or superior clinical outcomes compared to sustained oral precursor supplementation has not been demonstrated in a controlled comparison study. The dramatic acute blood NAD+ spike from IV may not reflect superior cellular delivery — and sustained cellular NAD+ elevation from regular oral supplementation may be pharmacologically more relevant than an acute IV spike. Community users report the IV infusion as producing a more dramatic immediate subjective experience (warmth, flushing, energy) than oral supplementation — consistent with a larger acute blood level change, not necessarily better therapeutic efficacy.
Unlike the healing peptides or GH secretagogues in this book, NAD+ precursors do not have evidence-based cycling requirements. NAD+ is a continuously required metabolite; there is no receptor downregulation concern, no HPTA suppression risk, and no known tolerance mechanism that would argue for cycling. Most clinical trials used continuous daily supplementation for 10-12 weeks. Long-term safety data beyond 12 weeks is limited but no concerning signals have emerged. Continuous daily supplementation is the clinical trial standard and the most pharmacologically sensible approach for a cofactor your cells require continuously.
No strong timing requirement from clinical data. Some practitioners recommend morning dosing because NAD+ is involved in the circadian clock regulation — NAD+ levels oscillate with circadian rhythm, and SIRT1 and NAMPT are core components of the molecular clock. The theoretical argument for morning dosing: align supplementation with the peak of the endogenous NAD+ cycle. The practical argument: take it whenever you'll remember consistently, as the primary variable is not timing but adherence. With food reduces the rare GI discomfort associated with NMN and NR supplementation.
NAD+ precursors have a genuinely good safety profile in the published clinical literature. No serious adverse events have been reported across multiple RCTs for NMN or NR at standard doses (up to 2,000 mg/day for NR; up to 1,200 mg/day for NMN) over trial durations of up to 12 weeks. NR with FDA GRAS status and the broadest regulatory approval history has the cleanest documented safety record. NMN's safety is documented across dozens of trials without concerning signals. This is a class of compounds with excellent short-term safety documentation.
NAD+ precursors are dietary supplements in most jurisdictions (with the NMN US regulatory complexity noted above). They are not WADA-prohibited. Athletes can use NMN, NR, and niacin without anti-doping concerns. This is one of the cleanest WADA statuses in the longevity section of this book — no prohibition, no S0 ambiguity, no named ban.
NAD+ supplementation is often the foundation of longevity stacks because it supports the cofactor requirements of multiple other compounds' mechanisms of action. It is genuinely non-redundant with most compounds in this book.
SS-31 addresses mitochondrial structure (cardiolipin stabilization, ETC supercomplex organization). NAD+ supports the metabolic cofactor requirements of those same ETC complexes. These are complementary layers of mitochondrial support: structural (SS-31) and biochemical (NAD+). The combination addresses both the hardware and the fuel chemistry simultaneously. This is the most mechanistically coherent mitochondrial stack in the book — the two most evidence-based mitochondrial compounds, operating through entirely different mechanisms.
MOTS-c activates AMPK via the AICAR pathway (metabolic signaling). AMPK activation upregulates NAMPT — the rate-limiting enzyme in NAD+ biosynthesis — creating a feedback loop where AMPK activation also increases endogenous NAD+ production. Adding exogenous NAD+ precursors amplifies this by supplying substrate. MOTS-c drives the metabolic signaling; NAD+ ensures the cofactor supply. Mechanistically non-redundant. Both address the same axis (metabolic aging and energy efficiency) from different directions. Both WADA S4 banned — athletes can't use MOTS-c; NAD+ precursors are unrestricted.
Quercetin is a natural flavonoid that inhibits CD38 — the primary NAD+ consumer in aging and inflamed tissue. Combining a NAD+ precursor (supply) with quercetin (reduce consumption) addresses both sides of the NAD+ deficit simultaneously. This combination is mechanistically coherent and widely used in the longevity community. Quercetin also has senolytic properties (part of the Dasatinib+Quercetin senolytic protocol), adding an independent anti-aging mechanism. No controlled comparison of NAD+ supplementation with vs without CD38 inhibition in humans has been published.
The sequencing logic: senolytic clearing (FOXO4-DRI or D+Q) removes senescent cells that are major sources of CD38 upregulation through their SASP inflammatory secretome. After senolytic clearing, CD38 activity should be lower, making NAD+ supplementation more effective (less consumption by CD38 in the cleared tissue microenvironment). This is mechanistically elegant — clear the cells driving CD38 upregulation, then replenish the NAD+ that CD38 was depleting. The clear-then-replenish sequencing makes sense both for NAD+ specifically and for the broader rebuild-after-clearing philosophy.
Blood NAD+ elevation confirmed within the first week at standard doses (250-500 mg NMN or NR). Subjective effects in this window are minimal and highly variable — most people report nothing; some report slightly improved energy. Do not use subjective first-week experience to judge long-term efficacy.
Some users report improved sleep quality and energy stability. These are the most consistently reported early subjective benefits. No validated objective marker available to most users confirms mechanism.
The window where metabolic and physical performance benefits emerge in clinical trials. If bloodwork access is available: fasting glucose, insulin, and liver enzymes may show modest improvements in metabolically compromised individuals. Physical performance benefits most evident in older adults who are exercising.
The range where the 'longevity' effects are theorized to operate. No biomarker test reliably confirms anti-aging benefit from NAD+ supplementation in this timeframe. The honest position: if you are metabolically healthier, exercising more effectively, and your liver enzymes are improved, the compound may be working. You cannot measure 'aging slower.'
Timeframe
What to Expect
Days 1-7
Blood NAD+ elevation confirmed within the first week at standard doses (250-500 mg NMN or NR). Subjective effects in this window are minimal and highly variable — most people report nothing; some report slightly improved energy. Do not use subjective first-week experience to judge long-term efficacy.
Week 2-4
Some users report improved sleep quality and energy stability. These are the most consistently reported early subjective benefits. No validated objective marker available to most users confirms mechanism.
Month 1-3
The window where metabolic and physical performance benefits emerge in clinical trials. If bloodwork access is available: fasting glucose, insulin, and liver enzymes may show modest improvements in metabolically compromised individuals. Physical performance benefits most evident in older adults who are exercising.
Month 3-6+
The range where the 'longevity' effects are theorized to operate. No biomarker test reliably confirms anti-aging benefit from NAD+ supplementation in this timeframe. The honest position: if you are metabolically healthier, exercising more effectively, and your liver enzymes are improved, the compound may be working. You cannot measure 'aging slower.'
The clinical trial evidence is clearest for specific populations: metabolically compromised adults (insulin resistance, prediabetes, NAFLD); older adults (50+) with declining physical function; individuals with documented NAD+ decline (measurable via specialized testing). The more metabolically healthy and younger you are, the less likely you are to notice subjective or objective benefit from NAD+ supplementation — not because it's not doing anything, but because a healthy baseline NAD+ system has less room for improvement from supplementation.
One of the most frustrating aspects of NAD+ supplementation is the limited ability to track whether it's working in ways that matter. Blood NAD+ testing is available (some specialty labs offer whole-blood NAD+ measurement; Jinfiniti is the most commonly referenced consumer option) — this tells you whether you are raising blood NAD+. It does not tell you whether you are raising NAD+ in specific tissues (muscle, brain, heart) where the biological effects matter. It does not tell you whether sirtuin or PARP activity is meaningfully increased. It does not tell you whether you are aging more slowly. The biomarker-to-clinical-outcome gap is real and wide.
Quality considerations for NAD+ precursors: NMN — purity verification (HPLC 98%+); Third-party COA; confirm molecular weight ~334 Da. Batch-to-batch consistency matters more than with peptides because NMN can oxidize in storage. Store in cool, dark, low-humidity conditions. NR — TruNiagen (ChromaDex) is the most regulated commercial option with the most documented human trial history. Generic NR supplements vary in quality. Niacinamide — simple, stable, well-characterized vitamin; any reputable supplement brand with USP verification is adequate.
The honest position on NAD+ in 2026: the most scientifically legitimate longevity target in this book — NAD+ decline is real, the consequences for cellular function are real, and raising it in animals produces genuinely impressive results. The human trial evidence shows reliable blood NAD+ elevation and modest clinical benefits for specific outcomes in specific populations. The commercial ecosystem has significantly outrun the clinical evidence. The two most prominent voices in this space both have financial interests in which precursor you buy. The independent meta-analyses — the ones without financial stakes in either NMN or NR — consistently find 'modest' and 'exaggeration may exist in the field.' Both the biology and the clinical skepticism deserve to be held simultaneously.
Verdin E. (2015) [1]. NAD+ in aging, metabolism, and neurodegeneration. Science. 350(6265):1208-1213. [Comprehensive review of NAD+ biology in aging; the most-cited scientific review in the field; not commercially conflicted]
Yoshino J, Baur JA, Imai SI. (2018) [2]. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metabolism. 27(3):513-528. [Comprehensive review including mechanisms and animal evidence; Imai lab commercial ties disclosed]
Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 372(6547):1224-1229. [The most widely cited positive NMN human RCT: 250 mg/day x 10 weeks in overweight postmenopausal prediabetic women; improved insulin sensitivity]
Trammell SAJ, Schmidt MS, Weidemann BJ, et al. (2016) [4]. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. 7:12948. [Foundational NR human PK study; blood NAD+ elevation confirmed]
Dollerup OL, Christensen B, Svart M, et al. (2018) [5]. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: Safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 108(2):343-353. [NR 1,000 mg/day x 12 weeks; no significant effect on insulin sensitivity — important negative result]
(2024). Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials. Critical Reviews in Food Science and Nutrition. doi:10.1080/10408398.2024.2387324. [THE critical meta-analysis: 'most clinically relevant outcomes were not significantly different'; 'exaggeration of benefits may exist in the field']
Wen J, et al. (2024). Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials. Cureus. PMC11365583. [10 RCTs, 437 patients; positive physical performance signal with NMN]
Piotrowicz K, Machica J, et al. (2025) [8]. The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis. Journal of Cachexia, Sarcopenia and Muscle. PMC12022230. [2025 meta-analysis: 'minimal benefits for sarcopenia and muscle performance in older adults' — most critical recent analysis]
Yang X, Lu A, et al. (2025) [9]. An Updated Review on the Mechanisms, Pre-Clinical and Clinical Comparisons of NMN and NR. Food Frontiers. doi:10.1002/fft2.511. [Comprehensive 2025 review; balanced treatment of both precursors]
Brenner C. (2022) [10]. Critique of David Sinclair's 'Lifespan.' Published academic critique. [Brenner's systematic critique of Sinclair's claims; note Brenner = ChromaDex/NR commercial alignment; Sinclair = MetroBiotech/NMN commercial alignment]
Multiple sources. (2024) [11]. Sinclair resigns as president, Academy for Health and Lifespan Research following dog aging supplement controversy. [Context for overhype concerns in the field]
Chini CCS, Tarragó MG, Chini EN. (2016) [12]. NAD and the aging process: Role in life, death and everything in between. Molecular and Cellular Endocrinology. 455:62-74. [CD38's role in NAD+ decline; the CD38/inflammation/NAD+ antagonism]
NAD+ is the most legitimate longevity target in this book and the most commercially exploited. These two things are not in tension — the legitimacy is precisely what made it commercially exploitable. The biology is real. The commercial claims have outrun the clinical evidence. Both deserve to be said clearly.
The central tension resolved: NAD+ declines with age in human tissue. The decline contributes to mitochondrial dysfunction, reduced DNA repair, impaired sirtuin signaling, and accelerated aging phenotypes. Restoring NAD+ in old mice reverses multiple aging phenotypes in multiple independent labs. The animal evidence is compelling and replicable. Human clinical trials find that NMN and NR reliably raise blood NAD+ levels and produce modest improvements in metabolic function and physical performance in specific populations. Independent meta-analyses in 2024-2025 consistently find that 'most clinically relevant outcomes were not significantly different' from placebo and that 'exaggeration of benefits may exist in the field.' Two of the most prominent voices advocating for specific NAD+ precursors — Sinclair for NMN, Brenner for NR — both have direct commercial interests in the precursor they advocate for. The truth likely lives between their positions: NAD+ supplementation probably does something modestly beneficial for aging humans, probably less dramatically than the commercial discourse implies, and probably through mechanisms that the current clinical trials haven't been long enough or large enough to fully characterize.
What the evidence currently supports with confidence: oral NMN or NR reliably raises blood NAD+; modest improvements in insulin sensitivity, physical performance, and liver enzymes in specific populations; a good safety profile. What the evidence does not support: 'reversing aging,' dramatic longevity extension, or a clear clinical superiority of expensive NMN/NR over cheap niacinamide for most applications.
NAD+ is the most legitimate longevity target in this book and the most commercially exploited. These two things are not in tension — the legitimacy is precisely what made it commercially exploitable. The biology is real. The commercial claims have outrun the clinical evidence. Both deserve to be said clearly.
The central tension resolved: NAD+ declines with age in human tissue. The decline contributes to mitochondrial dysfunction, reduced DNA repair, impaired sirtuin signaling, and accelerated aging phenotypes. Restoring NAD+ in old mice reverses multiple aging phenotypes in multiple independent labs. The animal evidence is compelling and replicable. Human clinical trials find that NMN and NR reliably raise blood NAD+ levels and produce modest improvements in metabolic function and physical performance in specific populations. Independent meta-analyses in 2024-2025 consistently find that 'most clinically relevant outcomes were not significantly different' from placebo and that 'exaggeration of benefits may exist in the field.' Two of the most prominent voices advocating for specific NAD+ precursors — Sinclair for NMN, Brenner for NR — both have direct commercial interests in the precursor they advocate for. The truth likely lives between their positions: NAD+ supplementation probably does something modestly beneficial for aging humans, probably less dramatically than the commercial discourse implies, and probably through mechanisms that the current clinical trials haven't been long enough or large enough to fully characterize.
What the evidence currently supports with confidence: oral NMN or NR reliably raises blood NAD+; modest improvements in insulin sensitivity, physical performance, and liver enzymes in specific populations; a good safety profile. What the evidence does not support: 'reversing aging,' dramatic longevity extension, or a clear clinical superiority of expensive NMN/NR over cheap niacinamide for most applications.
Are you metabolically compromised (insulin resistance, prediabetes, NAFLD, declining physical function after 50)? NAD+ supplementation is most likely to produce measurable benefit in your situation — the evidence for metabolic improvements is the most consistent finding. Start with 250-500 mg NMN or NR daily; or consider niacinamide 250-500 mg daily as a lower-cost alternative. Monitor fasting glucose, HbA1c, and liver enzymes at 3 months.
Are you healthy, under 40, and metabolically optimal? The clinical evidence for NAD+ supplementation in healthy young people is weakest. Your NAD+ system is likely functioning adequately. The argument for supplementation is primarily speculative longevity benefit — a reasonable bet at low cost (niacinamide) but not well-supported by current evidence for the premium-priced options.
Are you deciding between NMN and NR? The head-to-head evidence slightly favors NR for blood NAD+ elevation in some comparisons; NMN has more recent and actively growing clinical trial data. Pick one and stick with it for at least 3 months before evaluating. Don't switch repeatedly based on social media claims. Neither has clear clinical superiority over the other.
Are you considering niacinamide instead of NMN or NR? This is the most financially rational choice given the absence of head-to-head superiority evidence for the expensive precursors. Use niacinamide 250-500 mg/day (not niacin, which causes flushing; not doses above 1 gram/day which may inhibit sirtuins). If you want a middle path: niacinamide 250 mg + NMN or NR 250 mg gives a combination of precursors at lower cost than full doses of the expensive options alone.
— End of NAD+ —
THE PEPTIDE BIBLE | NAD+ (NMN / NR / Niacin) | For Research & Educational Purposes Only
NAD+ (nicotinamide adenine dinucleotide) is the essential coenzyme required for 500+ enzymatic reactions including oxidative phosphorylation, DNA repair (PARP enzymes), and sirtuin activation (epigenetic regulation). NAD+ levels decline approximately 50% between age 20 and 60 in human tissue — one of the most robustly established facts in aging biology. The decline results from decreased synthesis (NAMPT activity declines) and increased consumption (PARP activity rises with DNA damage; CD38 activity rises dramatically with inflammation and aging). The CD38 problem: aging and inflammation upregulate CD38, the primary NAD+ consumer, potentially limiting supplemental NAD+ precursors' ability to raise cellular NAD+ in tissues with high CD38 activity. Three primary precursor strategies: NMN (nicotinamide mononucleotide, ~$50-100/month, one step from NAD+, championed by Sinclair who is commercially aligned with MetroBiotech NMN); NR (nicotinamide riboside, ~$40-80/month, two steps from NAD+, championed by Brenner who is commercially aligned with ChromaDex/TruNiagen NR); and niacinamide (~$5-15/month, well-established NAD+ precursor, generic and unpatentable, rarely discussed in the commercial ecosystem). Commercial conflict: Sinclair (NMN) vs Brenner (NR) is partly scientific debate, partly commercial competition — both men have direct financial interests in their preferred precursor. Human clinical evidence: Blood NAD+ elevation is Grade A (reliable, consistent across RCTs). Clinical outcomes: modest and inconsistent across studies. 2024 meta-analysis finding: 'most clinically relevant outcomes were not significantly different from placebo'; 'exaggeration of benefits may exist in the field.' 2025 meta-analysis (Journal of Cachexia): 'minimal benefits for sarcopenia and muscle performance in older adults.' Best-supported clinical outcomes: insulin sensitivity improvement in metabolically compromised women (Yoshino 2021, Science); modest physical performance improvement in older adults; liver enzyme normalization. Standard dosing: NMN or NR 250-1,000 mg/day oral; niacinamide 250-500 mg/day (avoid >1g which may inhibit sirtuins). Safety: excellent across all trials; no serious adverse events. WADA: not prohibited for athletes. Regulatory: NR has broadest international regulatory approval (FDA GRAS, NDI); NMN US status complex; niacinamide is simple vitamin B3. The central tension: the most scientifically legitimate longevity target in this book — the biology is real, the animal evidence is compelling, and the commercial ecosystem has significantly outrun the human clinical evidence.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.